# A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

> **NCT05375929** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 200 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Abrocitinib 100 mg
- **DRUG:** Abrocitinib 200 mg

## Key facts

- **NCT ID:** NCT05375929
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-16
- **Primary completion:** 2023-06-09
- **Final completion:** 2024-03-14
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375929, "A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05375929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*